グルコースレベルを調節する糖呼吸グリコポリマーソーム
Yufen Xiao1, Hui Sun1, Jianzhong Du1,2
1Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University , 4800 Caoan Road, Shanghai 201804, China.
Journal of the American Chemical Society
|May 17, 2017
まとめ
この研究では インスリンや薬剤なしで 血糖値を調節する 新しい"砂糖スポンジ"ナノ構造を導入しました この革新的なアプローチは,天然のグルコース調節を模倣することで,糖尿病の新たな治療法となる可能性があります.
科学分野:
- バイオマテリアル科学
- ナノテクノロジー
- 内分泌学
背景:
- 糖尿病は慢性疾患で,血糖の調節のために毎日のインスリン注射が必要です.
- 現在の糖尿病の治療には しばしばインスリンを頻繁に投与することがあり 患者に負担をかけています
研究 の 目的:
- 新しいナノ構造を用いた 血糖調節のための非インスリン・薬物フリー・戦略を開発する.
- レクチン結合グリコポリマーソームがグルコース反応性治療剤としての可能性を調査する.
主な方法:
- レクチンで機能化されたグリコポリマーソーム (PEO-b-P ((CMA-stat-DEA-stat-GEMA)) の自己組み立て.
- サイズ変化を含むグルコース結合と放出のダイナミクスの in vitro 特徴づけ
- I型糖尿病のマウスにおける抗糖尿病効果のインビボ評価
主要な成果:
- その
- 砂糖スポンジ
- 濃度に基づいて動的グルコースの吸収と放出が示されています.
- グルコース反応を示す in vitro で顕著なサイズ変化が観察されました.
- 一回投与で糖尿病のマウスで2日以上有効な血糖コントロールを達成した.
結論:
- レクチンに結合したグリコポリマーソームは
- 砂糖スポンジ
- 血糖管理の新たなアプローチを提案しています.
- この戦略は 糖尿病の治療に インスリンや薬剤を 使わない 有望な代替手段です
- その
- 砂糖スポンジ
- このコンセプトは,糖尿病の治療の新たな道を開きます.
関連する概念動画
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
684
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
684
Hormones Regulating Blood Glucose
7.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.6K
Glucose Homeostasis: Regulation of Blood Glucose
4.8K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.8K
Oligosaccharide Assembly
3.8K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
3.8K
Biosynthesis of Polysaccharides
779
Polysaccharides such as glycogen and starch are synthesized from nucleoside diphosphate sugars, primarily uridine diphosphate glucose (UDPG) and adenosine diphosphate glucose (ADPG). These activated glucose donors act as key intermediates in carbohydrate metabolism and biosynthesis. UDPG primarily involves glycogen synthesis in animals and many bacteria, while ADPG plays a fundamental role in starch synthesis in plants and certain bacteria.UDPG is formed when glucose-1-phosphate reacts with...
779
Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K


